HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burke, R. E. Articles by Fahn, S. Search for Related Content PubMed PubMed Citation Articles by Burke, R. E. Articles by Fahn, S.

Serum trihexyphenidyl levels in the treatment of torsion dystonia

Department of Neurology, College of Physicians and Surgeons, Columbia University, and the Neurological Institute of Presbyterian Hospital, New York, NY.

Using a radioreceptor technique, we assayed serum trihexyphenidyl levels in patients with dystonia being treated chronically with high dosage. We found a significant correlation between total daily dose and the daily lowest (trough) serum levels. There was no relationship between serum levels and therapeutic response or toxicity. Toxicity was more closely related to patient age than to serum level. Although levels may be useful to monitor patient compliance, they cannot be used to judge adequacy of therapy.

Address correspondence and reprint requests to Dr. Burke, Department of Neurology, College of Physicians and Surgeons. Columbia University, 710 West 168th Street, New York, NY 10032.

This work was performed at the Dystonia Clinical Research Center at Columbia University, supported by the Dystonia Medical Research Foundation.

Accepted for publication October 25, 1984.

This article has been cited by other articles:

				T. D. Sanger Pathophysiology of Pediatric Movement Disorders J Child Neurol, January 1, 2003; 18(1_suppl): S9 - S24. [Abstract] [PDF]

				J. T. Greenamyre and C. F. O'Brien N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease Arch Neurol, September 1, 1991; 48(9): 977 - 981. [Abstract] [PDF]